ProfileGDS5678 / 1416253_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 91% 89% 88% 92% 89% 87% 89% 88% 88% 89% 88% 86% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0946190
GSM967853U87-EV human glioblastoma xenograft - Control 27.3807791
GSM967854U87-EV human glioblastoma xenograft - Control 36.971989
GSM967855U87-EV human glioblastoma xenograft - Control 46.9911588
GSM967856U87-EV human glioblastoma xenograft - Control 57.7387292
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8778689
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4297787
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.919589
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8778288
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8178288
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.949389
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0026988
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5343986
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9953889